Topical tacrolimus for atopic dermatitis (Q24186624)

title

Topical tacrolimus for atopic dermatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

1 reference

Aécio Flávio Teixeira de Góis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

Henrique Akira Ishii

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

3

Valeria Aoki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

1

Jade Cury Martins

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

author name string

Ciro Martins

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

Edina M K da Silva

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

Cochrane Database of Systematic Reviews

13 May 2020

publication date

1 July 2015

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

page(s)

CD009864

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Blinded side-to-side comparison of topical corticosteroid and tacrolimus ointment in children with moderate to severe atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Treatment of lichenified atopic eczema with tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Safe treatment of head/neck AD with tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A Randomized, Open-Label, Multicenter Trial of Topical Tacrolimus for the Treatment of Pruritis in Patients with Atopic Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Topical pimecrolimus for eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Dietary exclusions for established atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Topical treatment of Netherton's syndrome with tacrolimus ointment without significant systemic absorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

21 January 2018

10. Atopic dermatitis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Atopic eczema or atopiform dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The course of life of patients with childhood atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A systematic review of the safety of topical therapies for atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Tacrolimus ointment-associated alcohol intolerance in infants receiving ethanol-containing medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Effects of atopic dermatitis on young American children and their families

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Outcome measures of disease severity in atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Development of Kaposi's sarcoma in an AIDS patient after treatment with topical tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Alcohol-induced application site erythema after topical immunomodulator use and its inhibition by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Understanding and managing atopic dermatitis in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Diet and asthma, allergic rhinoconjunctivitis and atopic eczema symptom prevalence: an ecological analysis of the International Study of Asthma and Allergies in Childhood (ISAAC) data. ISAAC Phase One Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Atopic dermatitis and nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Rosaceiform dermatitis associated with topical tacrolimus treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Eczema, atopy and allergen exposure in adults: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Association between exposure to topical tacrolimus or pimecrolimus and cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Assessment of the SF-36 version 2 in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Non-melanoma skin cancers and glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Alcohol-induced rash caused by topical tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Superantigens in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The Safety and Efficacy of Tacrolimus Ointment in Pediatric Patients with Atopic Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Alcohol intolerance and facial flushing in patients treated with topical tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Inhibitory potency of tacrolimus ointment on skin tumor induction in a mouse model of an initiation-promotion skin tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The benefits and risks of long-term PUVA photochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a two-year, multicentre, non-comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Allergic contact dermatitis from tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Systemic therapy for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Important systemic absorption of topical tacrolimus during treatment of severe pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Allergic conditions and risk of hematological malignancies in adults: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

The risk of melanoma in association with long-term exposure to PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Hay fever, hygiene, and household size

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Calcineurin inhibitors and rapamycin: cancer protection or promotion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Retracted: Meta‐analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Labial melanotic macule after application of topical tacrolimus: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Topical tacrolimus for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD009864.PUB2

Immunodeficiency-associated lymphoproliferative disorders

21 January 2018

1 reference

12 December 2020

Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group

1 reference

12 December 2020

The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group

1 reference

12 December 2020

Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome.

1 reference

12 December 2020

Clinical features of atopic dermatitis at two years of age: a prospective, population-based case-control study

1 reference

12 December 2020

Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis

1 reference

12 December 2020

Efficacy and safety of topically applied tacrolimus ointment in patients with moderate to severe atopic dermatitis

1 reference

12 December 2020

Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis)

1 reference

12 December 2020

Pimecrolimus and tacrolimus: the US FDA public health advisory.

1 reference

12 December 2020

Systemic absorption of topical tacrolimus in Pyoderma gangrenosum.

1 reference

12 December 2020

[Kaposi's sarcoma in an AIDS patient after application of tacrolimus (Protopic)]

1 reference

12 December 2020

Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis

1 reference

12 December 2020

Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis

1 reference

12 December 2020

The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study

1 reference

12 December 2020

Long-term Safety and Efficacy of Tacrolimus Ointment for the Treatment of Atopic Dermatitis in Children

1 reference

12 December 2020

Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics

1 reference

12 December 2020

Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults

1 reference

12 December 2020

Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis

1 reference

12 December 2020

Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis

1 reference

12 December 2020

Short-term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus

1 reference

12 December 2020

Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: a multicentric, open label, phase III study

1 reference

12 December 2020

Tacrolimus ointment-induced relapse of schizophrenia: a case report

1 reference

12 December 2020

Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.

1 reference

12 December 2020

Effects of tacrolimus ointment on Toll-like receptors in atopic dermatitis

1 reference

12 December 2020

Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study

1 reference

12 December 2020

Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues

1 reference

12 December 2020

Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009

1 reference

12 December 2020

Tacrolimus-Induced Rosacea-Like Dermatitis: A Clinical Analysis of 16 Cases Associated with Tacrolimus Ointment Application

1 reference

12 December 2020

Induced Lentiginosis With Use of Topical Calcineurin Inhibitors

1 reference

12 December 2020

Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis

1 reference

12 December 2020

Pimecrolimus cream and Tacrolimus ointment in the treatment of atopic dermatitis: a pilot study on patient preference

1 reference

12 December 2020

Grading of the severity of atopic dermatitis

1 reference

12 December 2020

The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens

1 reference

12 December 2020

Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial

1 reference

12 December 2020

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group

1 reference

12 December 2020

10.1002/14651858.CD009864.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4075854

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

OpenCitations bibliographic resource ID

13 May 2020

4075854

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461158&resulttype=core&format=json

13 May 2020

PubMed publication ID

26132597

1 reference